PPMD to Host Landmark Duchenne Patient-Focused Compass Meeting

Join us in person or virtually!

As part of this year's Advocacy Conference (March 4-6, 2018), PPMD will host the Duchenne Patient-Focused Compass Meeting: Navigating our Pathway Forward. The meeting will be held on Monday, March 5, 2018 at the Mayflower Hotel in Washington, DC from 10 AM - 4 PM. The Duchenne Patient-Focused Compass meeting will be comprised of panels and presentations with Duchenne community members (patients and caregivers) to explore 'living with Duchenne,' clinical trial and therapeutic experiences, and access to services, supports, and approved therapies across the Duchenne spectrum.

Following a discussion with key FDA personnel last fall, our PPMD team has been working on developing a meeting format that utilizes the "FDA PFDD Workshop" framework, while also broadening the day's scope to apply to federal partners and stakeholders beyond FDA. We believe that this will allow us to build upon our community's work with the Duchenne Guidance, Patient Preferences studies, and formalized data collection. Invited members of FDA, NIH, CDC, CMS, and other federal agencies, along with relevant policy stakeholders will be present. Live polling of Duchenne families present and those viewing the meeting online will provide real time data about patient and caregiver perspectives and experiences.

In preparing for this meeting we have invited all of our Duchenne community foundation partners to join the Community Advisory Board (CAB) for this meeting. We currently have 15 Duchenne foundations signed onto the CAB.

CAB members include:

  • Best Day Ever Foundation
  • Coalition Duchenne
  • Foundation for a Future
  • Foundation to Eradicate Duchenne (FED)
  • Hope for Gus
  • Hope for Javier
  • JB's Keys
  • Jett Foundation
  • Little Hercules Foundation
  • Powers Promise
  • Ryan's Quest
  • Team Joseph
  • Walking Strong
  • Zach Heger Foundation

PPMD is grateful to all foundations participating in this effort!

In preparation for this important meeting, PPMD published a White Paper intended to reflect our current Duchenne landscape and create context for the March meeting. The White Paper was led by PPMD with the collaboration of the CAB. A meeting report will be published following the March 5 meeting.

We urge ALL members of the Duchenne/Becker community – parents and teens and adults to join us for this historic meeting.

For those unable to attend in person, virtual participation will be powerful and will include real-time polling throughout the day's discussions – please read below for more details about how YOU can help us shape our community's landscape on March 5th!

Why this Meeting? Why Now?

Since the passage of PDUFA V (during the reauthorization of and the launch of the Patient Focused Drug Development (PFDD) Initiative at the FDA, the agency has been holding a series of disease specific “Voice of the Patient” meetings with different patient communities. These meetings have followed a set “PFDD workshop formula” in order to elicit an understanding of a given disease area and to collect high-level information on burden of disease and symptom management.

In 2017, PPMD’s Duchenne Drug Development Roundtable (DDDR) partners worked together to evaluate our research and ‘regulatory learnings’ throughout 2015 and 2016. PPMD also convened meetings that explored the role of inflammation in Duchenne and the burden of clinical trial participation.

In addition, as a result of our community’s efforts around the MD-CARE Act Amendments of 2014 and a strong collaboration between the Centers for Disease Control and Prevention (CDC) and the Duchenne community, the Duchenne/Becker Care Considerations have been updated to reflect changing care standards. The DBMD Care Considerations were published last month (January 2018)

And just last week, the FDA published the finalized “Duchenne Muscular Dystrophy and Related Dystrophinopathies: Developing Drugs for Treatment” Guidance for Industry (click here to learn more and access the document). The publication was the result of years of work from multiple stakeholders in this community, including all of you who contributed your voice, your story to the initial draft guidance PPMD submitted in 2014.

We now want to ensure that we bring our patient community’s voice, perspective, and current experience of Duchenne into the center of this conversation. That is the purpose of the March 5 meeting.

How You Can Participate in the Meeting

We hope you will join us in person for both the Annual Advocacy Conference and this incredibly important milestone meeting for our Duchenne community.

For those unable to attend in person, not to worry, you can be part of this day too! We will be live streaming the meeting and everyone is welcome to join us virtually.  For United States families (patients, caregivers, family members) – we need your participation in this historic meeting by being a part of the day’s discussion and real-time polling/surveying throughout the meeting. Whether you are physically in the room in DC, or engaging from your home – your voice and experience matters and we urge you to join us on March 5.

To sign up to be a virtual attendee, please register here.

Views: 806


You need to be a member of PPMD Community to add comments!

Join PPMD Community

Need help using this community site? Visit Ning's Help Page.



© 2022   Created by PPMD.   Powered by

Badges  |  Report an Issue  |  Privacy Policy  |  Terms of Service